Post-transplant Lymphoproliferative Disorder Following Kidney Transplantation,

Yıl 2022, Cilt: 4 - Supplement 1, 158 - 159, 01.04.2022

Ömer Candar Tuğçe Zor Turna

https://doi.org/10.46310/tjim.1073449

Öz

Posttransplant lymphoproliferative diseases are complications that develop after solid organ transplantation. Primary EBV infection is one of the most important risk factors. After deceased kidney transplantation, we presented a young male patient diagnosed with diffuse large B-cell lymphoma.

Anahtar Kelimeler

Post-transplant, Lymphoproliferative Disorder, Kidney Transplantation

Proje Numarası

1

Kaynakça

• Maksten EF, Vase MØ, Kampmann J, d’Amore F, Møller MB, Strandhave C, Bendix K, Bistrup C, Thiesson HC, Søndergaard E, Hamilton-Dutoit S, Jespersen B. Post-transplant lymphoproliferative disorder following kidney transplantation: a population-based cohort study. Transpl Int. 2016 Apr;29(4):483- 93. doi: 10.1111/tri.12744.
• Bakker NA, van Imhoff GW, Verschuuren EA, van Son WJ. Presentation and early detection of post-transplant lymphoproliferative disorder after solid organ transplantation. Transpl Int. 2007 Mar;20(3):207-18. doi: 10.1111/j.1432- 2277.2006.00416.x.
• Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): Risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013 Sep;8(3):173-83. doi: 10.1007/s11899-013-0162-5.
• Green M, Michaels MG. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder. Am J Transplant. 2013 Feb;13 Suppl 3:41-54; quiz 54. doi: 10.1111/ajt.12004.
• Hutton B, Joseph L, Yazdi F, Tetzlaff J, Hersi M, Kokolo M, Fergusson N, Bennett A, Buenaventura C, Fergusson D, Tricco A, Strauss S, Moher D, Knoll G. Checking whether there is an increased risk of post-transplant lymphoproliferative disorder and other cancers with specific modern immunosuppression regimens in renal transplantation: protocol for a network meta- analysis of randomized and observational studies. Syst Rev. 2014 Feb 22;3:16. doi: 10.1186/2046-4053-3-16.